证券代码：603883 证券简称：老百姓 公告编号：2025-041 老百姓大药房连锁股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司2025年半年度报告披露工作的重要提醒》等相关要求，现将老百姓大药 房连锁股份有限公司（以下简称"公司"）2025年半年度主要经营数据披露如下： 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度(%) | | --- | --- | --- | | 营业收入 | 10,774,312,515 | -1.51 | | 归属于上市公 司股东的净利 | 397,863,893 | -20.86 | | 润 归属于上市公 | | | | 司股东的扣除 非经常性损益 | 381,121,690 | -20.89 | | 的净利润 | | | | 经营活动产生 的现金流量净 | 1,626,04 ...

Core Viewpoint - Yifeng Pharmacy Chain Co., Ltd. maintains a stable credit rating of AA for both the company and its convertible bonds, reflecting its strong market position and financial performance despite industry challenges [1][3][4]. Company Overview - Yifeng Pharmacy, established in June 2008, transitioned to a joint-stock company in August 2011 and was listed on the Shanghai Stock Exchange in February 2015 [11]. - As of March 2025, the company has a total share capital of 1.212 billion shares, with the largest shareholder holding 21.65% [11]. Financial Performance - In 2024, the company achieved a total revenue of 24.062 billion yuan, a year-on-year increase of 6.53%, and a profit of 2.182 billion yuan, up 7.11% [7][10]. - The net cash flow from operating activities was 4.221 billion yuan, fully covering the cash outflow from investment activities [7][10]. - As of the end of 2024, the company's total assets were 27.975 billion yuan, with total liabilities of 12.819 billion yuan, reflecting a debt increase of 28.02% from the previous year [8][10]. Market Position and Competitive Advantage - Yifeng Pharmacy is recognized as one of the leading pharmaceutical retail enterprises in China, ranking second in the "2024-2025 China Pharmacy Value List" [6][18]. - The company operates 14,684 retail chain stores, with 10,872 being directly operated, and has a strong presence in economically developed regions [6][18]. - The company has established a comprehensive supply chain and logistics system, ensuring efficient operations and store expansion [6][19]. Industry Analysis - The pharmaceutical retail industry in China is characterized by intense competition and a low concentration ratio, with significant room for growth in market share among leading companies [16][17]. - The industry is experiencing pressure from policies aimed at controlling medical insurance costs, which impacts profit margins [5][16]. - The demand for pharmaceutical products remains stable, with a notable increase in chronic disease management and health services [16][17]. Future Outlook - The company is expected to continue expanding its retail network and improve operational efficiency, which may enhance its overall strength in the market [4][5]. - Potential factors for rating upgrades include significant revenue and profit growth while maintaining reasonable financial leverage [4][5]. - Conversely, risks include adverse changes in industry policies and intensified competition, which could negatively impact profitability [5][6].

Core Viewpoint - The company is responding to an inquiry regarding its 2024 annual report, addressing concerns about revenue growth slowdown, net profit decline, and the stability of gross profit margins amidst industry challenges and regulatory changes [1][2]. Group 1: Financial Performance - The company's revenue for 2022, 2023, and 2024 was 20.176 billion, 22.437 billion, and 22.358 billion RMB, with year-on-year growth rates of 28.54%, 11.21%, and -0.36% respectively [2]. - The net profit attributable to shareholders for the same years was 0.785 billion, 0.929 billion, and 0.519 billion RMB, with year-on-year changes of 17.29%, 18.35%, and -44.13% respectively [2]. - The overall gross profit margin has shown stable growth, with the gross profit margin for 2024 at 41.4% compared to 39.6% in 2023 and 40.4% in 2022 [5]. Group 2: Industry Challenges - The pharmaceutical retail industry is experiencing revenue stagnation and profit pressure due to ongoing medical reforms, stricter insurance regulations, and increased market competition [3][4]. - The number of retail pharmacies in China reached 675,000 by the end of 2024, reflecting a growth of 1.21% from the previous year, indicating intensified competition in the market [4]. Group 3: Strategic Adjustments - In response to market conditions, the company has increased the number of self-built and franchised stores to enhance market share, with the total number of stores reaching 14,684 in 2024, up from 10,268 in 2022 [4]. - The company is shifting its product strategy towards traditional Chinese and Western medicines, with sales of these products accounting for 79.1% of total revenue in 2024 [5]. - The company has implemented measures to optimize its supply chain and improve operational efficiency, including a focus on private label products, which generated sales of 3.54 billion RMB in 2024, accounting for 22% of total sales [5][6]. Group 4: Goodwill and Asset Management - The company has a significant goodwill balance of 5.756 billion RMB as of the end of 2024, representing 27.35% of total assets, necessitating careful management and impairment testing of goodwill [2][3]. - The company conducts goodwill impairment tests based on asset groups defined by operational units, ensuring compliance with accounting standards [6][8].

Core Viewpoint - The company, Lao Bai Xing Pharmacy, has experienced significant fluctuations in performance over recent years, with stable growth in gross profit margin despite a decline in net profit and revenue growth slowdown. The company faces challenges from industry competition and regulatory changes in the healthcare sector [2][4]. Financial Performance - Revenue for the years 2022 to 2024 was reported as follows: 20.176 billion, 22.437 billion, and 22.358 billion RMB, with year-on-year changes of 28.54%, 11.21%, and -0.36% respectively. Net profit for the same period was 0.785 billion, 0.929 billion, and 0.519 billion RMB, with changes of 17.29%, 18.35%, and -44.13% respectively [2]. - The overall gross profit margin for the years was 31.88%, 32.56%, and 32.50% [2]. Business Strategy and Market Conditions - The company has been increasing the number of self-built and franchised stores to enhance market share, with total store numbers reaching 15,277 in 2024, up from 13,574 in 2023 and 10,783 in 2022 [6]. - The company is also focusing on online sales channels, with public domain B2C and O2O sales accounting for 10.3% of total revenue in 2024, up from 9.3% in 2023 and 6.6% in 2022 [6]. - The company has adjusted its product strategy to focus more on traditional Chinese and Western medicine, with sales of traditional Chinese and Western medicine accounting for 77.5% of total revenue in 2024 [7]. Industry Challenges - The retail pharmacy market is facing a slowdown in growth, with the total retail pharmacy market sales reaching 528.2 billion RMB in 2024, a year-on-year decline of 2.2% [5]. - The industry is experiencing increased competition, with a total of 675,000 pharmacies in China as of the end of 2024, serving an average of 2,000 people per pharmacy, compared to 5,000 in the United States [5]. Goodwill and Impairment - As of the end of 2024, the company's goodwill balance was 5.756 billion RMB, accounting for 27.35% of total assets. The company recognized a goodwill impairment provision of approximately 0.108 billion RMB for the year [2]. - The company classifies its goodwill based on regional divisions, and the impairment testing process is conducted in accordance with accounting standards [8][10]. Operational Efficiency - The company has implemented measures to improve operational efficiency, including restructuring product selection strategies, enhancing digital product introductions, and optimizing supply chain costs [7]. - The company’s gross profit margin has shown a continuous increase, with a comprehensive gross profit margin of 36.4% in 2024, up from 35.7% in 2023 [7].

Core Points - The annual shareholder meeting of Yifeng Pharmacy Chain Co., Ltd. is scheduled for May 29, 2025, in Changsha, Hunan Province [1] - The board of directors has prepared the 2024 annual report and submitted it for review at the shareholder meeting [4][20] - The company achieved a revenue of 24.06 billion yuan in 2024, representing an 8.26% increase year-on-year [6][25] - The net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 9.40% compared to the previous year [6] - The company opened 2,512 new stores during the year, focusing on a strategy of regional concentration and steady expansion [5][10] Financial Performance - The company reported a total revenue of 24,062,154,701.73 yuan in 2024, up from 22,588,227,402.22 yuan in 2023, marking a growth of 6.53% [25] - The total assets of the company reached 27,974,736,950.35 yuan, a 15.90% increase from the previous year [25] - The operating profit also showed steady growth, with a net profit attributable to shareholders increasing to 980,443.25 million yuan [6][25] Board and Governance - The board of directors held 17 meetings during the reporting period, reviewing 68 proposals, including matters related to stock options and management appointments [6][7] - The audit committee of the board held 4 meetings, reviewing 16 proposals to ensure compliance with internal controls and external audits [6][7] - The independent directors actively participated in decision-making and provided constructive opinions to protect the interests of all shareholders [8] Strategic Initiatives - The company is focusing on digital transformation, supply chain optimization, and new retail models to enhance its competitive edge [9][10] - A comprehensive digital link from customers to products and operations is being established to shift the focus from product management to customer management [5][10] - The company aims to enhance its core competitiveness through brand image improvement, professional service capabilities, and differentiated product offerings [9][10] Market and Operational Insights - The retail segment remains the primary revenue source, accounting for 90.95% of total revenue, with a gross margin of 38.36% [27][28] - The company has seen growth across various product categories, with traditional Chinese medicine and non-pharmaceutical products also contributing positively [27][28] - The company is expanding its market presence in Central South, East China, and North China regions, implementing tailored strategies for each city [10]

Group 1 - The report highlights that the company "老百姓" (603883) is focusing on its advantageous regions, with expectations for performance to gradually stabilize and improve [5][6][8] - In 2024, the company achieved operating revenue of 22.358 billion yuan, a year-on-year decrease of 0.36%, and a net profit attributable to shareholders of 519 million yuan, down 44.13% year-on-year [5][6] - The company experienced short-term performance decline due to factors such as losses from new store openings, store closures, and increased depreciation expenses [5][6][7] Group 2 - The retail business generated revenue of 19.107 billion yuan in 2024, a year-on-year decrease of 1.25%, while the franchise, alliance, and distribution business saw revenue of 3.105 billion yuan, an increase of 5.92% [6][7] - The company is expanding its new retail ecosystem, with online sales reaching approximately 2.47 billion yuan in 2024, a year-on-year increase of about 24% [6][7] - The company has increased its store count to 15,277 by the end of 2024, with a net increase of 1,703 stores, representing a year-on-year growth of 12.55% [8] Group 3 - The report indicates that the company is leveraging opportunities in lower-tier markets, with 80% of new stores in 2024 located in cities at the prefecture level and below [8] - The company plans to continue focusing on advantageous markets and accelerate the acquisition of existing market share, aiming to capitalize on industry consolidation opportunities [8] - The investment forecast for the company has been adjusted downwards for 2025 and 2026, with expected net profits of 692 million yuan, 799 million yuan, and 909 million yuan for 2025 to 2027 [8] Group 4 - The banking sector is experiencing rapid growth in social financing driven by government financing, with a year-on-year increase of 8.7% in social financing scale balance as of April [11][12] - The report notes that the marginal growth of loans is slowing, with the total new loans in April being 844 billion yuan, the lowest for the same period in recent years [12][13] - The People's Bank of China is expected to maintain a supportive monetary policy, with a focus on optimizing the structure of credit distribution [13][14]

Core Insights - The company reported a revenue of 26.497 billion yuan in 2024, representing an 8.01% increase, while the net profit attributable to shareholders was 915 million yuan, down 21.58% [1] - In Q1 2025, the company achieved a revenue of 6.956 billion yuan, a 3.02% increase, and a net profit of 460 million yuan, up 15.45% [2] - The company is focusing on optimizing its store layout and enhancing management efficiency as it enters a consolidation phase after completing its cross-province expansion [3] Revenue and Profit Analysis - In 2024, the company's Chinese and Western medicine revenue was 19.968 billion yuan, up 12.82%, with a gross margin of 30.00%, down 1.16 percentage points [2] - The revenue from traditional Chinese medicine was 2.945 billion yuan, down 0.99%, with a gross margin of 42.32%, down 0.56 percentage points [2] - Non-pharmaceutical revenue was 2.948 billion yuan, down 9.52%, with a gross margin of 41.72%, down 1.80 percentage points [2] Store Expansion and Management - As of Q1 2025, the company had a total of 16,622 stores across 21 provinces, with a net increase of 2,479 stores in 2024 [3] - The company closed 733 stores in 2024, while in Q1 2025, it opened 54 new stores and closed 174 [3] - The gross margin for 2024 was 34.33%, down 1.58 percentage points, attributed to declining consumer spending and a higher number of new stores in the cultivation phase [3] Technological Advancements - The company is embracing AI technology, launching systems for automatic replenishment, intelligent site selection, and smart promotions to enhance operational management [4] - The implementation of digital upgrades is expected to improve management efficiency, with sales and management expense ratios of 23.37% and 4.65%, respectively, showing slight increases [3] Investment Outlook - The company is projected to have EPS of 0.97, 1.14, and 1.35 yuan for the years 2025, 2026, and 2027, respectively [4] - As a leading chain pharmacy, the company is expected to benefit from ongoing industry consolidation and the trend of prescription outflow, which may enhance profitability [4]

Core Viewpoint - The company reported a mixed financial performance for 2024, with revenue growth but a decline in net profit, while the first quarter of 2025 shows signs of recovery in profitability [1][2][4]. Financial Performance Summary - For 2024, the company achieved a revenue of 26.497 billion yuan, with a net profit of 915 million yuan, reflecting year-on-year changes of +8.01% for revenue, -21.58% for net profit, and -22.42% for net profit excluding non-recurring items [1]. - In Q4 2024, revenue was 6.766 billion yuan, with a net profit of 57 million yuan, showing a year-on-year revenue decline of -0.63%, but significant increases in net profit of +820.48% and +240.71% for net profit excluding non-recurring items [1]. - For Q1 2025, revenue reached 6.956 billion yuan, with a net profit of 460 million yuan, indicating year-on-year growth of +3.02% for revenue and +15.45% for net profit [1]. Operational Strategy Summary - The company closed 733 stores in 2024 to optimize its store network, which is expected to improve profitability in the long run despite short-term revenue pressure [2]. - The performance of traditional Chinese and Western medicine segments remained stable, with revenue growth of +12.82% in 2024 and +5.80% in Q1 2025, while consumer products faced challenges with declines in revenue [2]. - The company is leveraging AI technology by integrating DeepSeek-R1's "AI Xiaosan" to enhance operational efficiency through improved customer service and analysis capabilities [2]. Expansion and Market Position Summary - The company continues to expand its store network, with a total of 16,622 stores as of Q1 2025, including 6,239 franchise stores, and a net increase of 2,479 stores in 2024 [3]. - Revenue from franchise and distribution business reached 3.940 billion yuan in 2024, growing by +15.12%, and 1.130 billion yuan in Q1 2025, growing by +25.34% [3]. - The company is making progress in establishing specialized pharmacy qualifications, with 248 DTP pharmacies and over 10,000 designated medical insurance stores by the end of 2024 [3]. Profit Forecast and Investment Outlook - The company is expected to see profit growth outpacing revenue growth in 2025, with projected net profits of 1.07 billion yuan, 1.23 billion yuan, and 1.40 billion yuan for 2025-2027, respectively [4]. - The company is anticipated to benefit from industry trends and network optimization, leading to improved performance and market share [4].

证券代码：603883 证券简称：老百姓 公告编号：2025-015 老百姓大药房连锁股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 2、主营业务分行业、分产品、分地区情况 （1）主要业务分行业情况 单位：元币种：人民币 | | | | | 营业 | 营业 | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | | | | 毛利 | 收入 | 成本 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率（%） | 比上 | 比上 | 增减 | | | | | | 年增 | 年增 | （百分 | | | | | | 减（%） | 减（%） | 点） | | 零售 | 4,467,271,752 | 2,751,664,279 | 38.40 | -4.62 | -3.80 | -0.52 | | 加盟、 联盟及 分销 | 903,432,031 | 780,314,750 | 13.63 | 10.29 | ...

Investment Rating - The report maintains an "Accumulate" rating for the company [4] Core Views - The company has optimized its store network by closing 733 stores in 2024, which is expected to enhance profitability despite short-term revenue pressure [7] - The company is embracing AI opportunities, launching "AI Xiaosan" to improve operational efficiency [7] - The company continues to expand its store network, with a total of 16,622 stores as of Q1 2025, including 6,239 franchise stores [7] - The company has made progress in obtaining professional pharmacy qualifications, with 248 DTP pharmacies and over 10,000 insurance designated stores by the end of 2024 [7] - The company is expected to see a profit growth that outpaces revenue growth in 2025, with projected net profits of 10.7 billion, 12.3 billion, and 14.0 billion for 2025-2027 [7] Financial Data Summary - In 2024, the company reported total revenue of 26,497 million, with a net profit of 915 million, reflecting a year-on-year growth of 8.01% and a decline in net profit of 21.58% [1][3] - The company’s revenue for Q1 2025 was 69,560 million, with a net profit of 4,600 million, showing a year-on-year growth of 3.02% and 15.45% respectively [1] - The company’s projected revenue growth rates for 2025-2027 are 10%, 12%, and 13% respectively [3] - The company’s PE ratio is projected to decrease from 21.0 in 2024 to 13.7 in 2027, indicating an improving valuation [3][10] Store Expansion and Performance - The company added 2,479 stores in 2024, with a net increase of 69 stores in Q1 2025 [7] - Franchise and distribution revenue reached 39.40 billion in 2024, growing by 15.12%, and 11.30 billion in Q1 2025, growing by 25.34% [7] Profitability and Financial Ratios - The company’s net profit margin is projected to improve from 3.5% in 2024 to 3.8% in 2027 [10] - The return on equity (ROE) is expected to increase from 13.3% in 2024 to 16.1% in 2027 [10] - The company’s asset-liability ratio is projected to decrease from 69.2% in 2024 to 65.4% in 2027, indicating improved financial stability [10]